|Patient-reported treatment challenges with ongoing anti-VEGF injections included:|
AMD=wet age-related macular degeneration, anti-VEGF=anti-vascular endothelial growth factor, CATT=Comparison of Age-Related Macular Degeneration Treatment Trials evaluating ranibizumab vs bevacizumab for treatment of nAMD, CNV=choroidal neovascularization, FA=fluorescein angiography, OCT=optical coherence tomography.
VISUDYNE® (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for VISUDYNE®.
Indication and Important Safety Information
References: 1. Shah GK. Understanding and managing PDA in nAMD. Retina Today. March 2017 insert. 2. Core JQ, Pistilli M, Daniel E, et al. Predominantly persistent subretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina. 2021;5(10):962-974. doi: 10.1016/j.oret.2021.06.003. 3. Core JQ, Pistilli M, Hua P, et al. Predominantly persistent intraretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina. 2022;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. 4. McClard CK, Wang R, Windham V, et al. Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol. 2021;6:e000669. doi:10.1136/bmjophth-2020-000669.